TNONW (Tenon Medical, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by TNONW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-05 | Wyatt D. Geist | Chief Innovation Officer | A | — | — |
| 2026-05-05 | Nathaniel A. Grawey | Chief Commercial Officer | A | — | — |
| 2026-03-05 | Kevin Williamson | Chief Financial Officer | M | — | — |
| 2026-01-05 | STEVEN M FOSTER | CEO and President | M | — | — |
| 2026-01-05 | Stephen Hochschuler | Director | MIXED | — | — |
| 2026-01-05 | IVAN HOWARD | Director | MIXED | — | — |
| 2026-01-05 | ROBERT K WEIGLE | Director | MIXED | — | — |
| 2026-01-05 | Richard Ferrari | Director | M | — | — |
| 2026-01-05 | RICHARD GINN | Chief Technology Officer | MIXED | — | — |
| 2026-01-05 | Kristine M Jacques | Director | M | — | — |
| 2026-01-05 | Kevin Williamson | Chief Financial Officer | MIXED | — | — |
| 2025-12-29 | ROBERT K WEIGLE | Director | M | — | — |
| 2025-12-29 | IVAN HOWARD | Director | M | — | — |
| 2025-12-22 | Kristine M Jacques | Director | A | — | — |
| 2025-12-19 | Kevin Williamson | Chief Financial Officer | M | — | — |
| 2025-11-18 | Wyatt D. Geist | Chief Innovation Officer | Buy | — | — |
| 2025-11-18 | STEVEN M FOSTER | CEO and President | Buy | — | — |
| 2025-11-18 | Nathaniel A. Grawey | Chief Commercial Officer | Buy | — | — |
| 2025-10-15 | STEVEN M FOSTER | CEO and President | A | — | — |
| 2025-10-15 | Kristine M Jacques | Director | A | — | — |
| 2025-10-15 | IVAN HOWARD | Director | A | — | — |
| 2025-10-15 | Richard Ferrari | Director | A | — | — |
| 2025-10-15 | RICHARD GINN | Chief Technology Officer | A | — | — |
| 2025-10-15 | Kevin Williamson | Chief Financial Officer | A | — | — |
| 2025-10-15 | ROBERT K WEIGLE | Director | A | — | — |
| 2025-10-15 | Stephen Hochschuler | Director | A | — | — |
| 2023-06-15 | STEVEN M VAN DICK | Chief Financial Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Innovation Officer | 644,735 | — |
| — | Chief Commercial Officer | 482,865 | — |
| — | CEO and President | 163,814 | — |
| — | Chief Technology Officer | 133,015 | — |
| — | Chief Financial Officer | 100,416 | — |
| — | Director | 70,764 | — |
| — | Chief Financial Officer | 43,593 | — |
| — | Director | 10,965 | — |
| — | Director | 10,146 | — |
| — | Director | 8,462 | — |
| — | Director | 7,938 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNONW quote page; the site-wide leaderboard is on the insider transactions hub.